The Day In Review: Biotech Keeps The Momentum Going

July 15, 2005 -- Although it was a summer Friday, biotech rose in active trading. The Centient Biotech 200 moved up 26 points to 3617.81, an increase of .72%. Momenta added on another 25%, Kosan was up 33%, and Genzyme moved $5 higher. Chiron continues to have manufacuring problems and the FDA wants another test of Pulminiq before approval, Adherex signed a complicated deal with Glaxo taking the rights to a cancer drug from Glaxo and granting an option to its own anti-cancer compound, Schering-Plough won FDA approval for a new form of Clarinex, and Novartis bought the OTC medication business from Bristol-Myers Squibb. More details...

Back to news